Mount Sinai Health System announced on Apr. 2 that it has become the first health system in the world to use a newly cleared minimally invasive treatment for liver cancer, which allows for more flexible scheduling and faster care. The TheraSphere Y-90 Any Day Dosing capability, now part of the TheraSphere360 Management Platform, delivers radiation directly to liver tumors through the bloodstream.
This development is important because hepatocellular carcinoma, the most common type of liver cancer, often requires coordinated and timely treatments. The new approach lets doctors at Mount Sinai treat patients on more days of the week, which can help reduce wait times and improve access to care.
The first three cases using this technology were performed on March 30 under Kirema Garcia-Reyes, MD, an interventional radiologist and Assistant Professor at Icahn School of Medicine at Mount Sinai. Edward Kim, MD, Director of Interventional Oncology and Professor at Icahn School of Medicine at Mount Sinai; and Robert Lookstein, MD, Professor at Icahn School of Medicine at Mount Sinai also contributed to these procedures.
TheraSphere Y-90 is a therapy that targets tumors from inside the body while protecting healthy tissue. It is used both to control cancer progression and to help some patients become eligible for liver transplantation. Traditionally, radioactive decay required treatments be scheduled only on certain days due to fixed dosing schedules. The Any Day Dosing feature removes these limitations by enabling flexible scheduling through digital workflow tools that support planning and coordination among medical teams.
“This is a significant milestone. With Any Day Dosing, we now have the ability to treat patients on more days of the week,” said Dr. Garcia-Reyes. “That can mean shorter wait times and more convenient scheduling during what is often a complex and time-sensitive treatment journey.”
The Mount Sinai Tisch Cancer Center continues its efforts in adopting technologies aimed at improving patient access and outcomes for those facing liver cancer.
